Trends and outcomes of modern staging of solitary plasmacytoma of bone

Rahma Warsame, Morie Gertz, Martha Lacy, Robert A. Kyle, Francis Buadi, David M Dingli, Philip R. Greipp, Suzanne R. Hayman, Shaji K Kumar, John A. Lust, Stephen J Russell, Thomas Elmer Witzig, Joseph R Mikhael, Nelson Leung, Steven R. Zeldenrust, S Vincent Rajkumar, Angela Dispenzieri

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Over the years, the definition of solitary plasmacytoma of bone (SPB) has shifted in part due to more modern testing capabilities. We hypothesized that outcomes data based on antiquated testing would not reflect outcomes using modern staging. To address both how widely applied adequate diagnostic staging is and what the progression rates of SPB as defined with state-of-the-art staging are, we performed a retrospective chart review of those patients with a diagnosis of SPB seen at our institution over the past decade. Two groups were studied: all patients with SPB (n = 127); and those patients referred to our institution for an indication other than progression (n = 91). The median PFS for those two groups were 26 months and 42 months, respectively. At baseline, only a minority of patients had state-of-the-art staging. The 5 patients with both modern imaging and a negative bone marrow had a 21 month PFS of 100%. Patients with plasmacytoma plus, one plasmacytoma but bone marrow consistent with monoclonal gammopathy of undetermined significance, fare worse than true SPB. The use of modern testing is imperative to characterize a patient's risk for progression. PET/CT plays an important role in the diagnostic work-up.

Original languageEnglish (US)
Pages (from-to)647-651
Number of pages5
JournalAmerican Journal of Hematology
Volume87
Issue number7
DOIs
StatePublished - Jul 2012

Fingerprint

Plasmacytoma
Bone and Bones
Bone Marrow
Monoclonal Gammopathy of Undetermined Significance

ASJC Scopus subject areas

  • Hematology

Cite this

Trends and outcomes of modern staging of solitary plasmacytoma of bone. / Warsame, Rahma; Gertz, Morie; Lacy, Martha; Kyle, Robert A.; Buadi, Francis; Dingli, David M; Greipp, Philip R.; Hayman, Suzanne R.; Kumar, Shaji K; Lust, John A.; Russell, Stephen J; Witzig, Thomas Elmer; Mikhael, Joseph R; Leung, Nelson; Zeldenrust, Steven R.; Rajkumar, S Vincent; Dispenzieri, Angela.

In: American Journal of Hematology, Vol. 87, No. 7, 07.2012, p. 647-651.

Research output: Contribution to journalArticle

Warsame, Rahma ; Gertz, Morie ; Lacy, Martha ; Kyle, Robert A. ; Buadi, Francis ; Dingli, David M ; Greipp, Philip R. ; Hayman, Suzanne R. ; Kumar, Shaji K ; Lust, John A. ; Russell, Stephen J ; Witzig, Thomas Elmer ; Mikhael, Joseph R ; Leung, Nelson ; Zeldenrust, Steven R. ; Rajkumar, S Vincent ; Dispenzieri, Angela. / Trends and outcomes of modern staging of solitary plasmacytoma of bone. In: American Journal of Hematology. 2012 ; Vol. 87, No. 7. pp. 647-651.
@article{0f76a3a877b0457ea29ddb51b532fbd7,
title = "Trends and outcomes of modern staging of solitary plasmacytoma of bone",
abstract = "Over the years, the definition of solitary plasmacytoma of bone (SPB) has shifted in part due to more modern testing capabilities. We hypothesized that outcomes data based on antiquated testing would not reflect outcomes using modern staging. To address both how widely applied adequate diagnostic staging is and what the progression rates of SPB as defined with state-of-the-art staging are, we performed a retrospective chart review of those patients with a diagnosis of SPB seen at our institution over the past decade. Two groups were studied: all patients with SPB (n = 127); and those patients referred to our institution for an indication other than progression (n = 91). The median PFS for those two groups were 26 months and 42 months, respectively. At baseline, only a minority of patients had state-of-the-art staging. The 5 patients with both modern imaging and a negative bone marrow had a 21 month PFS of 100{\%}. Patients with plasmacytoma plus, one plasmacytoma but bone marrow consistent with monoclonal gammopathy of undetermined significance, fare worse than true SPB. The use of modern testing is imperative to characterize a patient's risk for progression. PET/CT plays an important role in the diagnostic work-up.",
author = "Rahma Warsame and Morie Gertz and Martha Lacy and Kyle, {Robert A.} and Francis Buadi and Dingli, {David M} and Greipp, {Philip R.} and Hayman, {Suzanne R.} and Kumar, {Shaji K} and Lust, {John A.} and Russell, {Stephen J} and Witzig, {Thomas Elmer} and Mikhael, {Joseph R} and Nelson Leung and Zeldenrust, {Steven R.} and Rajkumar, {S Vincent} and Angela Dispenzieri",
year = "2012",
month = "7",
doi = "10.1002/ajh.23201",
language = "English (US)",
volume = "87",
pages = "647--651",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "7",

}

TY - JOUR

T1 - Trends and outcomes of modern staging of solitary plasmacytoma of bone

AU - Warsame, Rahma

AU - Gertz, Morie

AU - Lacy, Martha

AU - Kyle, Robert A.

AU - Buadi, Francis

AU - Dingli, David M

AU - Greipp, Philip R.

AU - Hayman, Suzanne R.

AU - Kumar, Shaji K

AU - Lust, John A.

AU - Russell, Stephen J

AU - Witzig, Thomas Elmer

AU - Mikhael, Joseph R

AU - Leung, Nelson

AU - Zeldenrust, Steven R.

AU - Rajkumar, S Vincent

AU - Dispenzieri, Angela

PY - 2012/7

Y1 - 2012/7

N2 - Over the years, the definition of solitary plasmacytoma of bone (SPB) has shifted in part due to more modern testing capabilities. We hypothesized that outcomes data based on antiquated testing would not reflect outcomes using modern staging. To address both how widely applied adequate diagnostic staging is and what the progression rates of SPB as defined with state-of-the-art staging are, we performed a retrospective chart review of those patients with a diagnosis of SPB seen at our institution over the past decade. Two groups were studied: all patients with SPB (n = 127); and those patients referred to our institution for an indication other than progression (n = 91). The median PFS for those two groups were 26 months and 42 months, respectively. At baseline, only a minority of patients had state-of-the-art staging. The 5 patients with both modern imaging and a negative bone marrow had a 21 month PFS of 100%. Patients with plasmacytoma plus, one plasmacytoma but bone marrow consistent with monoclonal gammopathy of undetermined significance, fare worse than true SPB. The use of modern testing is imperative to characterize a patient's risk for progression. PET/CT plays an important role in the diagnostic work-up.

AB - Over the years, the definition of solitary plasmacytoma of bone (SPB) has shifted in part due to more modern testing capabilities. We hypothesized that outcomes data based on antiquated testing would not reflect outcomes using modern staging. To address both how widely applied adequate diagnostic staging is and what the progression rates of SPB as defined with state-of-the-art staging are, we performed a retrospective chart review of those patients with a diagnosis of SPB seen at our institution over the past decade. Two groups were studied: all patients with SPB (n = 127); and those patients referred to our institution for an indication other than progression (n = 91). The median PFS for those two groups were 26 months and 42 months, respectively. At baseline, only a minority of patients had state-of-the-art staging. The 5 patients with both modern imaging and a negative bone marrow had a 21 month PFS of 100%. Patients with plasmacytoma plus, one plasmacytoma but bone marrow consistent with monoclonal gammopathy of undetermined significance, fare worse than true SPB. The use of modern testing is imperative to characterize a patient's risk for progression. PET/CT plays an important role in the diagnostic work-up.

UR - http://www.scopus.com/inward/record.url?scp=84862569366&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862569366&partnerID=8YFLogxK

U2 - 10.1002/ajh.23201

DO - 10.1002/ajh.23201

M3 - Article

C2 - 22549792

AN - SCOPUS:84862569366

VL - 87

SP - 647

EP - 651

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 7

ER -